Xolair 150 MG/ML syringeml

Ended Awarded Last action

Contract number
SPE2DR26FDAA9
Awardee
Awarding agency
Obligated
$37,901

Award facts

Contract value 100% obligated
$37,901.28 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Park Ridge, IL 60068, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $37,901.28 delivery order to DMS Pharmaceutical Group Inc. on May 5, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for Xolair 150 mg/ml syringes, with an ultimate completion date of May 27, 2026.

DMS Pharmaceutical Group Inc. is a woman-owned small business headquartered in Park Ridge, Illinois, operating as the sole regional prime vendor under PPV-G GEN V's single-award indefinite delivery contract (SPE2DX) with a $499.999 billion ceiling running through December 31, 2036. Place of performance is Park Ridge, IL. The order is firm fixed price with no set-aside designation.

Quick answers

Who was awarded contract SPE2DR26FDAA9?

SPE2DR26FDAA9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 5, 2026.

How much is contract SPE2DR26FDAA9 worth?

The government has obligated $37,901 on SPE2DR26FDAA9.

Is contract SPE2DR26FDAA9 an order under another contract?

Yes. SPE2DR26FDAA9 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.

Was contract SPE2DR26FDAA9 competed?

The extent of competition for SPE2DR26FDAA9 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award